Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in rheumatology will be read downstream.
Rheumatology
ICG works across rheumatology environments where treatment sequencing, comparative evidence, route of administration, specialist behavior, access, and field organization form one competitive system.
The work includes rheumatology competitive intelligence, rheumatoid and psoriatic arthritis, spondyloarthritis, head-to-head positioning, biosimilar entry, launch scenarios, field-force benchmarking, and longitudinal monitoring.
Position Is Created Across the Treatment Sequence.
Rheumatology competition is governed by comparative evidence, line of therapy, guideline position, safety interpretation, administration, contracting, and physician confidence built over time.
ICG reconstructs how those conditions interact across clinical, access, and commercial systems to show where positioning can change and where it is structurally constrained.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across rheumatology.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Launch-Scenario Assessment for IL-17 and JAK Therapies in Rheumatoid Arthritis in the United States and Germany
- Competitive Development Monitoring Across Psoriatic Arthritis and Ankylosing Spondylitis
- Head-to-Head Clinical Positioning of an IL-17 Therapy Against an Anti-TNF Standard
- Clinical-Development Assessment of Combination Strategies in Lupus
Regulatory, Access & Adoption
- Market-Access and Sequencing Architecture for Biologics in Rheumatoid Arthritis
- Reimbursement and Switching Assessment for Anti-TNF Biosimilars
- Access and Adoption Assessment for JAK Inhibitors in Selected European Markets
- Payer Response to Advanced Therapies in Psoriatic Arthritis
Launch & Commercial Architecture
- Field-Force and Commercial-Organization Benchmarking in Rheumatology Across Europe
- Launch Architecture for IL-17 and IL-23 Therapies in Rheumatic Disease
- Commercial-Organization Assessment for Rheumatoid-Arthritis Portfolios Outside the United States
- Specialist-Engagement Architecture Across Psoriasis, Psoriatic Arthritis and Spondyloarthritis
Manufacturing, Delivery & Systems
- Self-Injection and Packaging Assessment for Subcutaneous Biologics in Immunology
- Administration and Patient-Support Architecture for Advanced Rheumatology Therapies
- Supply and Device Readiness for High-Dose Auto-Injectors in Immunology
Longitudinal Monitoring & Portfolio
- Longitudinal Monitoring of IL-17, IL-23 and JAK Portfolios
- Competitive Monitoring Across Rheumatoid Arthritis and Spondyloarthritis
- Multi-Market Monitoring of Biologic and Biosimilar Entry in Rheumatology
Rheumatology Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.